PCSK9 and hyperlipidemia: Based on the results of this NMA, evolocumab demonstrated the lowest likelihood of causing adverse muscle effects compared to other PCSK9 inhibitors (bococizumab, alirocumab) and inclisiran.This makes evolocumab a promising lipid-lowering option for patients with both hyperlipidemia and muscle disease.